[1] Villanueva A. Hepatocellular carcinoma. N Engl J Med,2019,380:1450-1462.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin,2016,66:115-132.
[3] Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 2012,62:394-399.
[4] Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med,2008,359: 378-390.
[5] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med,2020;382:1894-1905.
[6] Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res,2019,25: 5449-5457.
[7] Kelley RK. Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer. N Engl J Med, 2020,382:1953-1955
[8] Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet,2019,393: 2404-2415.
[9] Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol,2019,20:282-296 |
